Abstract: A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death.

Abstract: Implantable stimulation devices are provided. Aspects of the devices include a multiplexed multi-electrode component configured for neural stimulation. The multiplexed multi-electrode component includes two or more individually addressable satellite electrode structures electrically coupled to a common conductor. The satellite structures include a hermetically sealed integrated circuit controller operatively coupled to one or more electrodes. Also provided are systems that include the devices of the invention, as well as methods of using the systems and devices in a variety of different applications.

Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.

Abstract: Apparatus and methods enable robust, reliable control for implantable medical devices, including cardiac pacemakers, defibrillators and cardiac resynchronization devices. Integrated circuits in the devices have minimized interfaces, can derive power from the interface signals, and have high voltage and latch-up protection. A device lead has a power generation circuit and a switching circuit using cascaded PMOS transistors for operating with a stable voltage despite fluctuations in the supplied voltage. The lead has control electronics that provide a very low impedance between an electrode and a lead conductor during most of the duration of a pacing pulse, but during a brief initial portion of the pacing pulse, provide a very high impedance to permit charging up a power supply that is local to the control electronics. A method of stabilizing the external impedance and a system for fault detection and fault recovery for an implantable device are also provided.

Abstract: Implantable stimulation devices are provided. Aspects of the devices include a multiplexed multi-electrode component configured for neural stimulation. The multiplexed multi-electrode component includes two or more individually addressable satellite electrode structures electrically coupled to a common conductor. The satellite structures include a hermetically sealed integrated circuit controller operatively coupled to one or more electrodes. Also provided are systems that include the devices of the invention, as well as methods of using the systems and devices in a variety of different applications.

Abstract: The present invention is directed to an implantable vascular prosthesis configured for use in a wide range of applications, such as treating aneurysms, maintaining patency in a vessel, and allowing for the controlled delivery of therapeutic agents to a vessel wall. The prosthesis comprises one or more helical sections coupled to one or more anchoring sections having a generally zig-zag or cell-like configuration. The prosthesis is configured to conform to a vessel wall without substantially remodeling the vessel, and further is configured to be precisely deployed in a vessel without shifting or foreshortening during deployment.

Abstract: The present invention provides methods for inhibiting the growth of androgen-independent prostate cancer tumor cells in a human comprising administering to the human. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived compounds useful in the alleviation of cancer.

Abstract: A system for management of workstation energy is provided. The system includes a workstation having an energy outlet operable to provide energy to the workstation, a workstation occupancy sensor disposed in the workstation, and a cluster energy manager coupled with the energy outlet and workstation occupancy sensor. The workstation may be connected in a workstation cluster. The workstation occupancy sensor may be operable to detect occupancy of the workstation. The cluster energy manager may have a distribution circuit configured to control energy provided to the energy outlet, the cluster energy manager operable to control the energy based on occupancy of the workstation and/or a network event. The cluster energy manager is operable to report occupancy or workstation energy consumption to a monitoring system.

Abstract: Continuous field tomography systems are provided. Aspects of systems include a data aggregating module configured to receive both continuous field tomography data and non-continuous field physiological data and produce an aggregated data product from these disparate types of data. Also provided are methods of using systems of the invention in a variety of different applications, including diagnostic and therapeutic applications. The systems and methods of the invention find use in a variety of different applications, such as cardiac related applications.

Abstract: Embodiments of the present invention enable robust, reliable control functionality for effectors present on intraluminal, e.g., vascular leads, as well as other types of implantable devices. Embodiments of the invention enable the required functionality for accurate long term control of effectors units, even ones present on multiplex carrier configurations, while provide for low power consumption. Aspects of the invention include implantable integrated circuits that have power extraction; energy storage; communication; and device configuration functional blocks, where these functional blocks are all present in a single integrated circuit on an intraluminal-sized support. Also provided by the invention are effector assemblies that include the integrated circuits, as well as implantable medical devices, e.g., pulse generators that include the same, as well as systems and kits thereof and methods of using the same, e.g., in pacing applications, including cardiac resynchronization therapy (CRT) applications.

Abstract: The present invention provides a new mechanical sensor approach to maneuvering catheters and other cardiac devices into blood outlets, with particular application to maneuvering cardiac devices into the coronary sinus and beyond. Additionally, the inventive sensing device provides assessment of the viability of branching veins and other potential device sites, such as within the coronary venous system.

Abstract: The present invention is directed to a delivery catheter for use in deploying a vascular prosthesis having a self-expanding helical section for use in a wide range of interventional applications. The delivery catheter comprises an elongated member having a helical ledge with a pitch selected to impose a predetermined amount of foreshortening on the vascular prosthesis during deployment. Methods of making and using the delivery catheter of the present invention also are provided.

Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders treatable by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.

Abstract: Methods for the prevention and/or alleviation of androgen-mediated disorders by administering a chroman-derived anti-androgen compound are provided by the present invention. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived anti-androgen compounds useful in the prevention and/or alleviation of androgen-mediated disorders, particularly prostate cancer.

Abstract: Systems and methods apply audible acoustic energy to cause vasodilation and/or to increase tissue perfusion.

Abstract: The present invention is directed to a delivery catheter for use in deploying a vascular prosthesis having a self-expanding radial distal section joined to a helical section for use in a wide range of interventional applications. The delivery catheter comprises an elongated member having a balloon disposed adjacent to a distal end of the member, means for engaging the distal section of the vascular prosthesis against axial translation, and a sheath that restrains the vascular prosthesis against the elongated member during transluminal delivery. The balloon also may be used to perform angioplasty of a stenosis located within the vessel prior to deployment of the vascular prosthesis. Methods of using the delivery catheter of the present invention also are provided.

Abstract: Systems and methods monitor and enable the use of a medical instrument that is configured to be operated in a prescribed manner. The systems and methods employ a use register sized and configured to be carried by the medical instrument, which comprises a memory field for recording a start date and time at an instance of first operation of the medical instrument. The systems and methods also employ a use monitoring controller, which is adapted and configured to be coupled to the use register. The use monitoring controller includes a start validation function that compares the start date and time to a present real date and time and provides a start validation output based upon the comparison. The use monitoring controller also includes an enablement function that enables operation of the medical instrument only if the start validation output meets prescribed criteria.

Abstract: An implantable integrated circuit structure comprising a conformal thin-film sealing layer for hermetically sealing circuitry layers is provided. Also disclosed are electrode structures, leads that include the same, implantable pulse generators that include the leads, as well as systems and kits having components thereof, other implantable devices utilizing the structures, and methods of making and using the subject structures.

Abstract: The present invention provides methods for inhibiting the growth of androgen-independent prostate cancer tumor cells in a human comprising administering to the human. The invention further provides pharmaceutical and nutraceutical compositions containing chroman-derived compounds useful in the alleviation of cancer.

Abstract: An applicator for delivering ultrasound energy that comprises an ultrasound transducer adapted and configured to be electrically coupled to an ultrasound generator. A housing carries the ultrasound transducer for use. An element supports the transducer within the housing. The element includes an elastic material having a hardness of about 30 Shore A to about 100 Shore A.